Tempus AI Aktie News

Cathie Wood bought shares of AMD, Tesla, and Tempus AI on Wednesday. AMD shares moved sharply lower after posting poorly received quarterly results.

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Ambry Genetics, a leader in clinical genomic testing, and now a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM), today announced its contribution to new research leveraging Multiplexed Assays of Variant Effect (MAVEs) studies to advance interpretation of hereditary cancer-linked genetic variants, published in Nature Communications. Led by researche...

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Ambry Genetics, a leader in clinical genomic testing, and now a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM), announced the completion of its one-millionth DNA/RNA test, underscoring the company's commitment to diagnostic accuracy. A decade ago, in an industry first, Ambry Genetics pioneered paired DNA/RNA testing for hereditary cancer and conti...

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced results from a new study demonstrating that its algorithmic test, Immune Profile Score (IPS), more accurately predicts outcomes for patients receiving immune checkpoint inhibitors (ICIs) than conventional biomarkers, including tumor mutational b...

Tempus AI (TEM) remains a resilient healthcare AI leader, with proprietary data driving traction and a clear buy opportunity amid recent volatility. TEM reported preliminary 2025 revenue of ~$1.27B (+30% organic growth) and >$1.1B total contract value, supporting a robust multi-year growth runway. 2026 guidance calls for 25% revenue growth to $1.59B and adjusted EBITDA expansion to ~$65M, with ...

Cathie Wood added to her stakes in Netflix, Tempus AI, and Kodiak AI on Wednesday. Netflix and Tempus AI are trading at least 35% below last year's highs.

Tempus AI is reaffirmed as a Strong Buy, with profitability arriving a year earlier than consensus, driven by robust revenue growth and successful Ambry Genetics integration. TEM is guided to $1.59B revenue and $65M adjusted EBITDA in 2026, outpacing analyst expectations and de-risking the investment case. Diagnostics segment shows strong pricing power, with Oncology ASP rising from $1,630 to o...

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the launch of Paige Predict, a suite of cutting-edge digital pathology applications that analyze hematoxylin and eosin (H&E) whole slide images to help inform testing decisions. The AI-powered solution is designed to predict the likely presence ...